​

Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DYN Stock Forecast

Dyne Therapeutics (DYN) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $47.00, with a high of $48.00 and a low of $46.00. This represents a 475.28% increase from the last price of $8.17.

$5 $14 $23 $32 $41 $50 High: $48 Avg: $47 Low: $46 Last Closed Price: $8.17

DYN Stock Rating

Dyne Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 9 Buy (81.82%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 9 1 Strong Sell Sell Hold Buy Strong Buy

DYN Price Target Upside V Benchmarks

TypeNameUpside
StockDyne Therapeutics475.28%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-210
Avg Price Target-$47.00$46.70
Last Closing Price$8.17$8.17$8.17
Upside/Downside-475.28%471.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25671--14
Mar, 25471--12
Feb, 25471--12
Jan, 25471--12
Dec, 24471--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025UBS$48.00$13.61252.68%487.52%
Feb 28, 2025H.C. Wainwright$46.00$13.61237.99%463.04%
Aug 14, 2024Michael UlzMorgan Stanley$52.00$43.6419.16%536.47%
Aug 13, 2024Edward TenthoffPiper Sandler$53.00$43.0723.06%548.71%
Jun 24, 2024Eun YangJefferies$42.00$35.9416.86%414.08%
Jun 17, 2024Francois BriseboisOppenheimer$55.00$32.1571.07%573.19%
May 21, 2024Keay NakaeChardan Capital$42.00$35.3818.71%414.08%
May 20, 2024Andrew FeinH.C. Wainwright$48.00$33.8341.89%487.52%
May 20, 2024Paul MatteisStifel Nicolaus$41.00$27.6848.12%401.84%
Apr 30, 2024Michael UlzMorgan Stanley$40.00$25.4657.11%389.60%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankOutperforminitialise
Jan 10, 2025H.C. WainwrightBuyBuyhold
Jan 10, 2025RBC CapitalOutperformOutperformhold
Sep 23, 2024Piper SandlerOverweightOverweighthold
Sep 03, 2024OppenheimerOutperformOutperformhold
Aug 14, 2024Morgan StanleyOverweightOverweighthold
Aug 13, 2024Piper SandlerOverweightOverweighthold
Aug 13, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024JefferiesBuyBuyhold
Jun 17, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.95$-3.37----
Avg Forecast$-3.78$-3.47$-3.76$-3.83$-3.12$-1.16
High Forecast$-3.61$-3.16$-2.83$-3.10$-1.76$-1.16
Low Forecast$-3.95$-3.84$-4.75$-4.79$-3.92$-1.16
Surprise %4.50%-2.88%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$833.33K$9.56M$192.28M$500.80M
High Forecast--$833.33K$9.56M$192.28M$500.80M
Low Forecast--$833.33K$9.56M$192.28M$500.80M
Surprise %------

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-235.94M$-317.42M----
Avg Forecast$-225.57M$-208.96M$-226.32M$-235.37M$-169.58M$-69.23M
High Forecast$-215.66M$-188.82M$-169.04M$-184.84M$-105.33M$-69.23M
Low Forecast$-235.48M$-229.11M$-283.60M$-285.89M$-233.82M$-69.23M
Surprise %4.60%51.90%----

DYN Forecast FAQ

Is Dyne Therapeutics stock a buy?

Dyne Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Dyne Therapeutics is a favorable investment for most analysts.

What is Dyne Therapeutics's price target?

Dyne Therapeutics's price target, set by 11 Wall Street analysts, averages $47 over the next 12 months. The price target range spans from $46 at the low end to $48 at the high end, suggesting a potential 475.28% change from the previous closing price of $8.17.

How does Dyne Therapeutics stock forecast compare to its benchmarks?

Dyne Therapeutics's stock forecast shows a 475.28% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Dyne Therapeutics over the past three months?

  • April 2025: 42.86% Strong Buy, 50.00% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Dyne Therapeutics’s EPS forecast?

Dyne Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.76, marking a 11.57% increase from the reported $-3.37 in 2024. Estimates for the following years are $-3.83 in 2026, $-3.12 in 2027, and $-1.16 in 2028.

What is Dyne Therapeutics’s revenue forecast?

Dyne Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $833.33K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $9.56M, followed by $192.28M for 2027, and $500.8M for 2028.

What is Dyne Therapeutics’s net income forecast?

Dyne Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-226M, representing a -28.70% decrease from the reported $-317M in 2024. Projections indicate $-235M in 2026, $-170M in 2027, and $-69.233M in 2028.